Galectin-3 inhibitor GB0139 protects against acute lung injury by inhibiting neutrophil recruitment and activation

• Main Authors: Duncan C. Humphries (Author), Ross Mills (Author), Cecilia Boz (Author), Brian J. McHugh (Author), Nikhil Hirani (Author), Adriano G. Rossi (Author), Anders Pedersen (Author), Hans T. Schambye (Author), Robert J. Slack (Author), Hakon Leffler (Author), Ulf J. Nilsson (Author), Wei Wang (Author), Tariq Sethi (Author), Alison C. Mackinnon (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Rationale: Galectin-3 (Gal-3) drives fibrosis during chronic lung injury, however, its role in acute lung injury (ALI) remains unknown. Effective pharmacological therapies available for ALI are limited; identifying novel concepts in treatment is essential. GB0139 is a Gal-3 inhibitor currently under...